Coenzyme Q9 (CoQ9) Bioproduction Engineering Service

Coenzyme Q9 (CoQ9), a lipophilic molecule, is a crucial component of the electron transport chain, offering strong antioxidant properties. While Coenzyme Q10 (CoQ10) is more common in commercial health products, CoQ9 is a major form in bacteria like Escherichia coli. Industrial production via fermentation is challenging due to low microbial fermentation yield ; the CoQ9 synthesis pathway is lengthy, tightly regulated, and carbon flux is often diverted to competing pathways (e.g., tRNA modification). Furthermore, CoQ9's hydrophobic nature means it is stored within cell membranes, resulting in difficult extraction from the microbial biomass, increasing downstream costs. Biosynthesis optimization is needed to redirect flux and enhance recovery.

CD Biosynsis offers a synthetic biology service focused on high-yield Coenzyme Q9 production in Escherichia coli. Our core strategy involves modification of terpenoid synthesis pathway in Escherichia coli . CoQ9 is composed of a quinone ring and a nine-unit isoprenoid tail. We employ metabolic engineering to enhance the precursor supply from the MEP (Methylerythritol Phosphate) pathway, specifically focusing on the intermediate solanesyl diphosphate (SPP), which forms the CoQ9 side chain. We eliminate flux leakage to other terpenoids (like carotenoids). This is coupled with overexpression of coenzyme Q9 synthase . The final steps of CoQ9 synthesis involve several methylation and hydroxylation reactions catalyzed by a multi-enzyme complex. We introduce and heavily overexpress the complete CoQ synthesis operon (UbiA, UbiB, UbiC, UbiD, UbiE, UbiF, UbiG, UbiH, UbiI) in conjunction with a specialized Prenyltransferase (IspB) to ensure the nine-unit length. This integrated approach aims to deliver a high-titer CoQ9 product by maximizing carbon flux toward the quinone precursor and the isoprenoid chain, while streamlining the final enzymatic conversion.

Pain Points

Developing a cost-effective CoQ9 production route faces these key limitations:

• Low Microbial Fermentation Yield: The synthesis pathway involves a large number of enzyme steps from central carbon metabolism, and flux is difficult to maintain and regulate, resulting in a low overall carbon yield.
• Difficult Extraction: CoQ9 is highly hydrophobic and primarily integrated into the inner cell membrane, requiring intense, toxic organic solvent extraction and cell disruption steps, leading to high processing costs.
• Precursor Imbalance: The two major precursors, the quinone ring (from Chorismate) and the isoprenoid side chain (from MEP pathway), are often not produced at balanced rates , limiting the final output.
• Pathway Competition: The isoprenoid precursors (IPP) are shared with the synthesis of many other essential cellular components, causing carbon leakage and reducing yield.

A successful solution must coordinate the synthesis of both the head group and the tail group, while also facilitating product recovery.

Solutions

CD Biosynsis utilizes advanced metabolic engineering to optimize Coenzyme Q9 production in E. coli:

Modification of Terpenoid Synthesis Pathway in E. coli

           

We overexpress rate-limiting enzymes in the MEP pathway and tune the expression of Prenyltransferase (IspB) to ensure maximum supply of the C45 isoprenoid tail (SPP).

Overexpression of Coenzyme Q9 Synthase

We introduce and overexpress the entire ubi operon and the prenyltransferase gene to ensure the rapid and complete conversion of precursors into final CoQ9.

Quinone Precursor Optimization

We modify the central aromatic pathway (Shikimate pathway) to increase the supply of 4-hydroxybenzoic acid (4-HB) , the key precursor for the quinone ring.

Metabolite Excretion Engineering

We explore the overexpression of membrane transporters or the use of specific micro-emulsion conditions to encourage the secretion and accumulation of CoQ9 into the medium, simplifying recovery.

This systematic approach is focused on balancing the flux of the dual-precursor pathway and facilitating the cost-effective recovery of the final hydrophobic product.

Advantages

Our CoQ9 engineering service is dedicated to pursuing the following production goals:

Significantly Increased Titer

Flux balancing and Ubi operon overexpression leads to a higher final accumulation of CoQ9 compared to wild-type strains.

Simplified Extraction and Reduced Cost

Engineering the strain to excrete the product reduces the need for harsh cell disruption and organic solvent extraction, lowering costs. [Image of Cost Reduction Icon]

High Specificity for CoQ9

Precise control of Prenyltransferase (IspB) ensures the synthesis of the desired nine-unit isoprenoid tail , minimizing undesired CoQ8 or CoQ10 production.

Non-GMO or Food-Grade Options

Optimization can be performed in hosts like Pichia pastoris or Saccharomyces cerevisiae to meet food and cosmetic regulatory standards .

Enhanced Antioxidant Status

The biosynthetic route produces the reduced ubiquinol form , which has superior antioxidant activity compared to the oxidized quinone form.

We provide a specialized platform for the cost-effective, high-yield biomanufacturing of Coenzyme Q9.

Process

Our CoQ9 strain engineering service follows a rigorous, multi-stage research workflow:

• Precursor Pathway Reinforcement: Overexpress the MEP pathway and key genes (AroG, AroB) in the Shikimate pathway to maximize the supply of SPP and 4-HB.
• Quinone Biosynthesis Cluster Assembly: Integrate and overexpress the full ubi operon (UbiA through UbiI) with the specific Prenyltransferase (IspB) for C45 side chain length.
• Competing Pathway Deletion: Knock out flux-diverting pathways (e.g., those synthesizing other isoprenoids or tRNA modification) to maximize CoQ9 carbon yield.
• Excretion System Design: Explore the use of membrane vesicle formation or specific cell wall modifications to facilitate product release into the medium.
• Fermentation Performance Validation: Test the final engineered strain in fed-batch fermentation to assess CoQ9 titer, yield, and purity (CoQ9 as % of total CoQ).
• Result Report Output: Compile a detailed Experimental Report including gene modification data, metabolic flux analysis, and fermentation metrics (volumetric titer and recovery efficiency) , supporting industrial scale-up.

Technical communication is maintained throughout the process, focusing on timely feedback regarding yield and product specificity.

Explore the potential for a high-titer, easily recoverable CoQ9 supply. CD Biosynsis provides customized strain and pathway engineering solutions:

• Detailed Titer and Isoprenoid Chain Length Analysis Report , demonstrating the specificity and yield of CoQ9.
• Consultation on optimized E. coli membrane permeabilization or excretion strategies for efficient downstream processing.
• Experimental reports include complete raw data on total CoQ9 production (mg/L) and the CoQ8/CoQ9/CoQ10 ratio , essential for quality control.